Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 50 % of short-term debt in 2025; threshold 65 %.
-
Figures corrected NBB
Corrected annual account filed for 2023.
Financials
Financial year 2025
MEDIPHARM ANDERLECHT from Evere, company number BE0803351426, closed financial year 2025 with a result of € 32,003 after tax. For that financial year MEDIPHARM ANDERLECHT recorded a gross margin of € 210,418 and equity of € 17,978. Compared with financial year 2024, the result moved from € -31,369 to € 32,003. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 15, 2026.
€ 17,978
▲ € 32,003 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 32,003
▲ still € 31,369 loss in 2024
Profit after tax over the fiscal year.
€ 56,927
▼ 3% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 14,978.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 165,204
▲ 9% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 9,236
▲ 10% vs 2024
Loans from banks and other lenders, long and short.
€ 97,474
▼ 22% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 21,752
▼ 16% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 100,332 | € 132,033 | € 210,418 | ▲ 59% |
| Profit after taxes | € 14,344 | € -31,369 | € 32,003 | ▲ € 63,373 |
| Equity | € 17,344 | € -14,025 | € 17,978 | ▲ € 32,003 |
| Total debts | € 261,302 | € 276,442 | € 267,644 | ▼ 3% |
| Cash | € 70,101 | € 58,578 | € 56,927 | ▼ 3% |
| Retained profit | € 14,344 | € -17,025 | € 14,978 | ▲ € 32,003 |
| Bank debt | € 0 | € 8,366 | € 9,236 | ▲ 10% |
| Balance sheet total | € 278,646 | € 262,417 | € 285,622 | ▲ 9% |
Key figures of MEDIPHARM ANDERLECHT, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MEDIPHARM ANDERLECHT?
What happened at MEDIPHARM ANDERLECHT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 32,003. filed late Source: NBB ↗
- New establishment in Evere. KBO
- Samer CHEAIB became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 14,344 profit in 2023 to € 32,003 profit in 2025.
Paid € 7,994 in corporate taxes since 2023.
Best year ever: 2025, with € 32,003 profit.
A new publication or filing at MEDIPHARM ANDERLECHT? We notify you, reason included.
Follow MEDIPHARM ANDERLECHTDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind MEDIPHARM ANDERLECHT is Samer CHEAIB. Samer CHEAIB is also behind MEDIPHARM and PHARMACIE HAYAT.
Directors
According to the 2025 annual accounts
since 2023
Establishments
Establishment units
Physical locations of this company
Provencewandelwegen 40
1140 Evere
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0803.351.426
- VAT number
- BE 0803.351.426
- Registered office
- Provencewandelwegen 40, 1140 Evere
- Names & denominations
- MEDIPHARM ANDERLECHT
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 June 2023
- Peppol
- Active · Active since 5 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten